![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SP Robinson, SM Langan-Fahey, DA Johnson and VC Jordan
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.
The metabolism of tamoxifen was examined in the rat, mouse, and human breast cancer patient. Large oral doses of tamoxifen (200 mg/kg) in the immature ovariectomized rat and mature mouse produced circulating levels of the parent compound, N-desmethyltamoxifen, and 4- hydroxytamoxifen quantifiable by HPLC separation, UV activation, and fluorescence detection. N-Desmethyltamoxifen and 4-hydroxytamoxifen serum levels in the mature ovariectomized mouse paralleled tamoxifen levels throughout a 96-hr time course after a single dose of tamoxifen. On the other hand, N-desmethyltamoxifen was the predominant serum metabolite after an equivalent dose of tamoxifen to the immature rat, but there was little 4-hydroxytamoxifen. Peak levels of tamoxifen occurred 3-6 hr after oral administration of tamoxifen in both species, whereas peak levels of N-desmethyltamoxifen in the immature rat did not occur until 24-48 hr. AUCs for tamoxifen and N-desmethyltamoxifen were approximately 4 times greater in the rat (57.5 and 111 micrograms.hr/ml, respectively) than the mouse (15.9 and 26.3 micrograms.hr/ml, respectively) after equivalent doses of tamoxifen (200 mg/kg). AUC of 4-hydroxytamoxifen for the rat (8.9 micrograms.hr/ml), however, was similar to that for the mouse (13.9 micrograms.hr/ml). The rate of elimination from serum was similar for tamoxifen, N-desmethyltamoxifen, and 4-hydroxytamoxifen in both the rat (t1/2 = 10.3, 12.1, and 17.2 hr, respectively) and the mouse (t1/2 = 11.9, 9.6, and 6 hr, respectively). Administration of large oral doses of tamoxifen (200 mg/kg) every 24 hr to mature ovariectomized mice or immature ovariectomized rats resulted in accumulation for the first 4 days.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamaya, M. Saeki, K.-i. Yoshida, J. Shibata, S. Yano, Y. Sato, A. Takao, T. Shindo, A. U. Buzdar, and S. Nagayama DISTRIBUTION OF (7{alpha})-21-[4-[(DIETHYLAMINO) METHYL]-2-METHOXYPHENOXY]-7-METHYL-19-NORPREGNA-1,3,5(10)-TRIEN-3-OL-20-[14C]2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE ([14C]TAS-108) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7,12-DIMETHYLBENZ({alpha})ANTHRACENE-INDUCED MAMMARY TUMOR Drug Metab. Dispos., February 1, 2006; 34(2): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, F. Cerrato, and A. Baldini Timed mutation and cell-fate mapping reveal reiterated roles of Tbx1 during embryogenesis, and a crucial function during segmentation of the pharyngeal system via regulation of endoderm expansion Development, October 1, 2005; 132(19): 4387 - 4395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fitts, R. M. Klein, and C. A. Powers Comparison of Tamoxifen and Testosterone Propionate in Male Rats: Differential Prevention of Orchidectomy Effects on Sex Organs, Bone Mass, Growth, and the Growth Hormone-IGF-I Axis J Androl, July 1, 2004; 25(4): 523 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ickenstein and S. M. Bandiera Persistent Suppression of Hepatic CYP2A1 Expression and Serum Triiodothyronine Levels by Tamoxifen in Intact Female Rats: Dose-Response Analysis and Comparison with 4-Hydroxytamoxifen, Fulvestrant (ICI 182,780), and 17beta -Estradiol-3-benzoate J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 584 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Guerrieri-Gonzaga, L. Baglietto, H. Johansson, B. Bonanni, C. Robertson, M.-T. Sandri, L. Canigiula, C. Lampreda, S. Diani, E. A. Lien, et al. Correlation between Tamoxifen Elimination and Biomarker Recovery in a Primary Prevention Trial Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 967 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mandlekar, V. Hebbar, K. Christov, and A-N. T. Kong Pharmacodynamics of Tamoxifen and Its 4-Hydroxy and N-Desmethyl Metabolites: Activation of Caspases and Induction of Apoptosis in Rat Mammary Tumors and in Human Breast Cancer Cell Lines Cancer Res., December 1, 2000; 60(23): 6601 - 6606. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Schafer, E. S. Lee, R. M. O'Regan, K. Yao, and V. C. Jordan Rapid Development of Tamoxifen-stimulated Mutant p53 Breast Tumors (T47D) in Athymic Mice Clin. Cancer Res., November 1, 2000; 6(11): 4373 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hunter, L. C. Hodges, P. M. Vonier, R. Fuchs-Young, M. M. Gottardis, and C. L. Walker Estrogen Receptor Activation via Activation Function 2 Predicts Agonism of Xenoestrogens in Normal and Neoplastic Cells of the Uterine Myometrium Cancer Res., July 1, 1999; 59(13): 3090 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O'Regan and V. C. Jordan RESPONSE: Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, June 2, 1999; 91(11): 973 - 973. [Full Text] [PDF]
|
|
|
|
|
|
R. M. O'Regan, A. Cisnero, G. M. England, J. I. MacGregor, H. D. Muenzner, V. J. Assiki, M. M. Bilimoria, M. Piette, Y. P. Dragan, H. C. Pitot, et al. Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, October 21, 1998; 90(20): 1552 - 1558. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Steinmetz, N. A. Mitchner, A. Grant, D. L. Allen, R. M. Bigsby, and N. Ben-Jonathan The Xenoestrogen Bisphenol A Induces Growth, Differentiation, and c-fos Gene Expression in the Female Reproductive Tract Endocrinology, June 1, 1998; 139(6): 2741 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Burroughs, K. Kiguchi, S. R. Howe, R. Fuchs-Young, D. Trono, J. C. Barrett, and C. Walker Regulation of Apoptosis in Uterine Leiomyomata Endocrinology, July 1, 1997; 138(7): 3056 - 3064. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
